An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-10-26

AUTHORS

Benjamin R. Underwood, Zeyn W. Green-Thompson, Peter J. Pugh, Stanley E. Lazic, Sarah L. Mason, Jules Griffin, P. Simon Jones, James B. Rowe, David C. Rubinsztein, Roger A. Barker

ABSTRACT

Preclinical data have shown that rilmenidine can regulate autophagy in models of Huntington's disease (HD), providing a potential route to alter the disease course in patients. Consequently, a 2-year open-label study examining the tolerability and feasibility of rilmenidine in mild-moderate HD was undertaken. 18 non-demented patients with mild to moderate HD took daily doses of 1 mg Rilmenidine for 6 months and 2 mg for a further 18 months followed by a 3-month washout period. The primary outcome was the number of withdrawals and serious adverse events. Secondary outcomes included safety parameters and changes in disease-specific variables, such as motor, cognitive and functional performance, structural MRI and serum metabolomic analysis. 12 patients completed the study; reasons for withdrawal included problems tolerating study procedures (MRI, and venepuncture), depression requiring hospital admission and logistical reasons. Three serious adverse events were recorded, including hospitalisation for depression, but none were thought to be drug-related. Changes in secondary outcomes were analysed as the annual rate of change in the study group. The overall change was comparable to changes seen in recent large observational studies in HD patients, though direct statistical comparisons to these studies were not made. Chronic oral administration of rilmenidine is feasible and well-tolerated and future, larger, placebo-controlled, studies in HD are warranted. TRIAL REGISTRATION: EudraCT number 2009-018119-14. More... »

PAGES

2457-2463

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00415-017-8647-0

DOI

http://dx.doi.org/10.1007/s00415-017-8647-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092407062

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29075837


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic alpha-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Huntington Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Longitudinal Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolomics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuropsychological Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rilmenidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Fulbourn Hospital, Fulbourn, Cambridge, CB21 5EF UK", 
          "id": "http://www.grid.ac/institutes/grid.415163.4", 
          "name": [
            "Fulbourn Hospital, Fulbourn, Cambridge, CB21 5EF UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Underwood", 
        "givenName": "Benjamin R.", 
        "id": "sg:person.01012741005.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012741005.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Addenbrooke\u2019s Hospital, Hills Road, Cambridge, CB21 2QQ UK", 
          "id": "http://www.grid.ac/institutes/grid.120073.7", 
          "name": [
            "Addenbrooke\u2019s Hospital, Hills Road, Cambridge, CB21 2QQ UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green-Thompson", 
        "givenName": "Zeyn W.", 
        "id": "sg:person.01244365253.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244365253.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Addenbrooke\u2019s Hospital, Hills Road, Cambridge, CB21 2QQ UK", 
          "id": "http://www.grid.ac/institutes/grid.120073.7", 
          "name": [
            "Addenbrooke\u2019s Hospital, Hills Road, Cambridge, CB21 2QQ UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pugh", 
        "givenName": "Peter J.", 
        "id": "sg:person.0703455320.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703455320.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Quantitative Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG UK", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "Quantitative Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lazic", 
        "givenName": "Stanley E.", 
        "id": "sg:person.01143475656.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143475656.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY UK", 
          "id": "http://www.grid.ac/institutes/grid.5335.0", 
          "name": [
            "UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mason", 
        "givenName": "Sarah L.", 
        "id": "sg:person.01256130314.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256130314.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA UK", 
          "id": "http://www.grid.ac/institutes/grid.5335.0", 
          "name": [
            "Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Griffin", 
        "givenName": "Jules", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK", 
          "id": "http://www.grid.ac/institutes/grid.415036.5", 
          "name": [
            "Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "P. Simon", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK", 
          "id": "http://www.grid.ac/institutes/grid.415036.5", 
          "name": [
            "Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rowe", 
        "givenName": "James B.", 
        "id": "sg:person.013473241432.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013473241432.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY UK", 
          "id": "http://www.grid.ac/institutes/grid.5335.0", 
          "name": [
            "Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK", 
            "UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rubinsztein", 
        "givenName": "David C.", 
        "id": "sg:person.01364457173.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364457173.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "John Van Geest Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 0PY UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Addenbrooke\u2019s Hospital, Hills Road, Cambridge, CB21 2QQ UK", 
            "Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK", 
            "John Van Geest Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 0PY UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barker", 
        "givenName": "Roger A.", 
        "id": "sg:person.01104460675.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104460675.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ng0893-398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001162353", 
          "https://doi.org/10.1038/ng0893-398"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-10-26", 
    "datePublishedReg": "2017-10-26", 
    "description": "Preclinical data have shown that rilmenidine can regulate autophagy in models of Huntington's disease (HD), providing a potential route to alter the disease course in patients. Consequently, a 2-year open-label study examining the tolerability and feasibility of rilmenidine in mild-moderate HD was undertaken. 18 non-demented patients with mild to moderate HD took daily doses of 1\u00a0mg Rilmenidine for 6\u00a0months and 2\u00a0mg for a further 18\u00a0months followed by a 3-month washout period. The primary outcome was the number of withdrawals and serious adverse events. Secondary outcomes included safety parameters and changes in disease-specific variables, such as motor, cognitive and functional performance, structural MRI and serum metabolomic analysis. 12 patients completed the study; reasons for withdrawal included problems tolerating study procedures (MRI, and venepuncture), depression requiring hospital admission and logistical reasons. Three serious adverse events were recorded, including hospitalisation for depression, but none were thought to be drug-related. Changes in secondary outcomes were analysed as the annual rate of change in the study group. The overall change was comparable to changes seen in recent large observational studies in HD patients, though direct statistical comparisons to these studies were not made. Chronic oral administration of rilmenidine is feasible and well-tolerated and future, larger, placebo-controlled, studies in HD are warranted.\nTRIAL REGISTRATION: EudraCT number 2009-018119-14.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00415-017-8647-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2785012", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.3864363", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.3639485", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.4579569", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6446046", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7444390", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2767200", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2770378", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1014525", 
        "issn": [
          "0340-5354", 
          "1432-1459"
        ], 
        "name": "Journal of Neurology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "264"
      }
    ], 
    "keywords": [
      "open-label study", 
      "serious adverse events", 
      "Huntington's disease", 
      "Secondary outcomes", 
      "adverse events", 
      "recent large observational studies", 
      "chronic oral administration", 
      "serum metabolomics analysis", 
      "large observational studies", 
      "non-demented patients", 
      "moderate Huntington's disease", 
      "disease-specific variables", 
      "number of withdrawals", 
      "disease course", 
      "primary outcome", 
      "hospital admission", 
      "washout period", 
      "HD patients", 
      "daily doses", 
      "preclinical data", 
      "oral administration", 
      "study group", 
      "observational study", 
      "rilmenidine", 
      "number 2009", 
      "patients", 
      "structural MRI", 
      "disease", 
      "study procedures", 
      "direct statistical comparison", 
      "tolerability", 
      "safety parameters", 
      "mild\u2013moderate Huntington\u2019s disease", 
      "outcomes", 
      "metabolomic analysis", 
      "functional performance", 
      "logistical reasons", 
      "months", 
      "depression", 
      "withdrawal", 
      "annual rate", 
      "overall change", 
      "statistical comparison", 
      "hospitalisation", 
      "admission", 
      "study", 
      "doses", 
      "administration", 
      "MRI", 
      "treatment", 
      "changes", 
      "autophagy", 
      "events", 
      "potential route", 
      "group", 
      "course", 
      "period", 
      "feasibility", 
      "reasons", 
      "rate", 
      "procedure", 
      "data", 
      "variables", 
      "number", 
      "comparison", 
      "analysis", 
      "route", 
      "motor", 
      "future", 
      "model", 
      "parameters", 
      "problem", 
      "performance", 
      "feasibility of rilmenidine", 
      "tolerability of rilmenidine"
    ], 
    "name": "An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington\u2019s disease", 
    "pagination": "2457-2463", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092407062"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00415-017-8647-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29075837"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00415-017-8647-0", 
      "https://app.dimensions.ai/details/publication/pub.1092407062"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_748.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00415-017-8647-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00415-017-8647-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00415-017-8647-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00415-017-8647-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00415-017-8647-0'


 

This table displays all metadata directly associated to this object as RDF triples.

318 TRIPLES      22 PREDICATES      122 URIs      113 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00415-017-8647-0 schema:about N117a459e11104ae98d6d23ca0b318f57
2 N11ad250127f740d782577daba3bc61bf
3 N16109212b7344affaf9e7e90821a735d
4 N1ff100728e994a089820f9956218553a
5 N2b8885d605b54d9d975037efb3029803
6 N307b0c954613451fbb60318b49495c82
7 N3b051486a600407f93258ef5596bc52a
8 N5ae798403101490ebaad3044d6582fcb
9 N6068987188b54a6da3670c0698d31d26
10 N67aeaafe7d364cc09a2ae4f60731bdd6
11 N943d302667d149b8b47f7bab2c9a9419
12 N9dfadb39a5ca4425aebec95aa9ccfd5f
13 Na5dfdb1ec75845cf81efeaadc98a8659
14 Nac0ca8ab11eb4f2bb7673c2def1724c9
15 Nbd31b3fe829a4f9bb4c5a1e8bb8f81f5
16 Nc5de9fb4255a4f489f1ada8f76e96c93
17 Nd33c65377aa44eeca35289590ae9889b
18 Nd3ee50c21c9b473c9ed2c213c7866f36
19 Necc94311a26e4d9fbbe4e2e8231a10bb
20 Nf462c629a6de42f2bd958657797a57c1
21 anzsrc-for:11
22 anzsrc-for:1117
23 schema:author N2acb30c30a4e4fb5a7f9dadcbd2695b1
24 schema:citation sg:pub.10.1038/ng0893-398
25 schema:datePublished 2017-10-26
26 schema:datePublishedReg 2017-10-26
27 schema:description Preclinical data have shown that rilmenidine can regulate autophagy in models of Huntington's disease (HD), providing a potential route to alter the disease course in patients. Consequently, a 2-year open-label study examining the tolerability and feasibility of rilmenidine in mild-moderate HD was undertaken. 18 non-demented patients with mild to moderate HD took daily doses of 1 mg Rilmenidine for 6 months and 2 mg for a further 18 months followed by a 3-month washout period. The primary outcome was the number of withdrawals and serious adverse events. Secondary outcomes included safety parameters and changes in disease-specific variables, such as motor, cognitive and functional performance, structural MRI and serum metabolomic analysis. 12 patients completed the study; reasons for withdrawal included problems tolerating study procedures (MRI, and venepuncture), depression requiring hospital admission and logistical reasons. Three serious adverse events were recorded, including hospitalisation for depression, but none were thought to be drug-related. Changes in secondary outcomes were analysed as the annual rate of change in the study group. The overall change was comparable to changes seen in recent large observational studies in HD patients, though direct statistical comparisons to these studies were not made. Chronic oral administration of rilmenidine is feasible and well-tolerated and future, larger, placebo-controlled, studies in HD are warranted. TRIAL REGISTRATION: EudraCT number 2009-018119-14.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N0bb79ba920e24079bece8eadaafba969
32 N40b5113e20dc429d9baac8ec4d3fe6ef
33 sg:journal.1014525
34 schema:keywords HD patients
35 Huntington's disease
36 MRI
37 Secondary outcomes
38 administration
39 admission
40 adverse events
41 analysis
42 annual rate
43 autophagy
44 changes
45 chronic oral administration
46 comparison
47 course
48 daily doses
49 data
50 depression
51 direct statistical comparison
52 disease
53 disease course
54 disease-specific variables
55 doses
56 events
57 feasibility
58 feasibility of rilmenidine
59 functional performance
60 future
61 group
62 hospital admission
63 hospitalisation
64 large observational studies
65 logistical reasons
66 metabolomic analysis
67 mild–moderate Huntington’s disease
68 model
69 moderate Huntington's disease
70 months
71 motor
72 non-demented patients
73 number
74 number 2009
75 number of withdrawals
76 observational study
77 open-label study
78 oral administration
79 outcomes
80 overall change
81 parameters
82 patients
83 performance
84 period
85 potential route
86 preclinical data
87 primary outcome
88 problem
89 procedure
90 rate
91 reasons
92 recent large observational studies
93 rilmenidine
94 route
95 safety parameters
96 serious adverse events
97 serum metabolomics analysis
98 statistical comparison
99 structural MRI
100 study
101 study group
102 study procedures
103 tolerability
104 tolerability of rilmenidine
105 treatment
106 variables
107 washout period
108 withdrawal
109 schema:name An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease
110 schema:pagination 2457-2463
111 schema:productId N4672fafbb10e42a1899590217f12dead
112 N4f2a2706efa84b299697374ccc42f5b1
113 N9a17a5a38d364749896c49d8c35d4620
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092407062
115 https://doi.org/10.1007/s00415-017-8647-0
116 schema:sdDatePublished 2021-12-01T19:41
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N58f8fb88f20b4e38af937bb631024e6f
119 schema:url https://doi.org/10.1007/s00415-017-8647-0
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N03eeb29deece484589eb780fe0f6194a schema:affiliation grid-institutes:grid.415036.5
124 schema:familyName Jones
125 schema:givenName P. Simon
126 rdf:type schema:Person
127 N0bb79ba920e24079bece8eadaafba969 schema:volumeNumber 264
128 rdf:type schema:PublicationVolume
129 N117a459e11104ae98d6d23ca0b318f57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Aged
131 rdf:type schema:DefinedTerm
132 N11ad250127f740d782577daba3bc61bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Magnetic Resonance Imaging
134 rdf:type schema:DefinedTerm
135 N16109212b7344affaf9e7e90821a735d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Metabolomics
137 rdf:type schema:DefinedTerm
138 N1ff100728e994a089820f9956218553a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Neuropsychological Tests
140 rdf:type schema:DefinedTerm
141 N2acb30c30a4e4fb5a7f9dadcbd2695b1 rdf:first sg:person.01012741005.50
142 rdf:rest N8e435b65043f4ffa8c9fa1c2c8745cd2
143 N2b8885d605b54d9d975037efb3029803 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Adrenergic alpha-Agonists
145 rdf:type schema:DefinedTerm
146 N2f619b3a8dd6464583674b732165a3c2 rdf:first sg:person.01364457173.35
147 rdf:rest Nf7bd5d8a600e4532a00d7f834f2d87a8
148 N307b0c954613451fbb60318b49495c82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Oxazoles
150 rdf:type schema:DefinedTerm
151 N3b051486a600407f93258ef5596bc52a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Rilmenidine
153 rdf:type schema:DefinedTerm
154 N40b5113e20dc429d9baac8ec4d3fe6ef schema:issueNumber 12
155 rdf:type schema:PublicationIssue
156 N4672fafbb10e42a1899590217f12dead schema:name doi
157 schema:value 10.1007/s00415-017-8647-0
158 rdf:type schema:PropertyValue
159 N4f2a2706efa84b299697374ccc42f5b1 schema:name dimensions_id
160 schema:value pub.1092407062
161 rdf:type schema:PropertyValue
162 N58f8fb88f20b4e38af937bb631024e6f schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 N5ae798403101490ebaad3044d6582fcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Young Adult
166 rdf:type schema:DefinedTerm
167 N6068987188b54a6da3670c0698d31d26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Longitudinal Studies
169 rdf:type schema:DefinedTerm
170 N63a9cbe212844a6b837d45647d484c42 rdf:first sg:person.013473241432.70
171 rdf:rest N2f619b3a8dd6464583674b732165a3c2
172 N66bd854288314a708d184cdaf13e7465 rdf:first sg:person.0703455320.69
173 rdf:rest N979facd2edff43f098a74bb8d5080534
174 N67aeaafe7d364cc09a2ae4f60731bdd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Huntington Disease
176 rdf:type schema:DefinedTerm
177 N8e435b65043f4ffa8c9fa1c2c8745cd2 rdf:first sg:person.01244365253.48
178 rdf:rest N66bd854288314a708d184cdaf13e7465
179 N943d302667d149b8b47f7bab2c9a9419 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Brain
181 rdf:type schema:DefinedTerm
182 N979facd2edff43f098a74bb8d5080534 rdf:first sg:person.01143475656.63
183 rdf:rest Nb951f954999d426bbd3705d61066db61
184 N97a06221a12c46c3827b7c998e88f07e schema:affiliation grid-institutes:grid.5335.0
185 schema:familyName Griffin
186 schema:givenName Jules
187 rdf:type schema:Person
188 N9a17a5a38d364749896c49d8c35d4620 schema:name pubmed_id
189 schema:value 29075837
190 rdf:type schema:PropertyValue
191 N9dfadb39a5ca4425aebec95aa9ccfd5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Time Factors
193 rdf:type schema:DefinedTerm
194 Na5dfdb1ec75845cf81efeaadc98a8659 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Adolescent
196 rdf:type schema:DefinedTerm
197 Nac0ca8ab11eb4f2bb7673c2def1724c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Male
199 rdf:type schema:DefinedTerm
200 Nb951f954999d426bbd3705d61066db61 rdf:first sg:person.01256130314.05
201 rdf:rest Nfca46a10fb9e4eb38522b2ce90bcb53a
202 Nbd31b3fe829a4f9bb4c5a1e8bb8f81f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Adult
204 rdf:type schema:DefinedTerm
205 Nc5de9fb4255a4f489f1ada8f76e96c93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Female
207 rdf:type schema:DefinedTerm
208 Nc990a1e9e05f492988710bf22f366873 rdf:first N03eeb29deece484589eb780fe0f6194a
209 rdf:rest N63a9cbe212844a6b837d45647d484c42
210 Nd33c65377aa44eeca35289590ae9889b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Treatment Outcome
212 rdf:type schema:DefinedTerm
213 Nd3ee50c21c9b473c9ed2c213c7866f36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Middle Aged
215 rdf:type schema:DefinedTerm
216 Necc94311a26e4d9fbbe4e2e8231a10bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Humans
218 rdf:type schema:DefinedTerm
219 Nf462c629a6de42f2bd958657797a57c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Retrospective Studies
221 rdf:type schema:DefinedTerm
222 Nf7bd5d8a600e4532a00d7f834f2d87a8 rdf:first sg:person.01104460675.05
223 rdf:rest rdf:nil
224 Nfca46a10fb9e4eb38522b2ce90bcb53a rdf:first N97a06221a12c46c3827b7c998e88f07e
225 rdf:rest Nc990a1e9e05f492988710bf22f366873
226 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
227 schema:name Medical and Health Sciences
228 rdf:type schema:DefinedTerm
229 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
230 schema:name Public Health and Health Services
231 rdf:type schema:DefinedTerm
232 sg:grant.2767200 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
233 rdf:type schema:MonetaryGrant
234 sg:grant.2770378 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
235 rdf:type schema:MonetaryGrant
236 sg:grant.2785012 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
237 rdf:type schema:MonetaryGrant
238 sg:grant.3639485 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
239 rdf:type schema:MonetaryGrant
240 sg:grant.3864363 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
241 rdf:type schema:MonetaryGrant
242 sg:grant.4579569 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
243 rdf:type schema:MonetaryGrant
244 sg:grant.6446046 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
245 rdf:type schema:MonetaryGrant
246 sg:grant.7444390 http://pending.schema.org/fundedItem sg:pub.10.1007/s00415-017-8647-0
247 rdf:type schema:MonetaryGrant
248 sg:journal.1014525 schema:issn 0340-5354
249 1432-1459
250 schema:name Journal of Neurology
251 schema:publisher Springer Nature
252 rdf:type schema:Periodical
253 sg:person.01012741005.50 schema:affiliation grid-institutes:grid.415163.4
254 schema:familyName Underwood
255 schema:givenName Benjamin R.
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012741005.50
257 rdf:type schema:Person
258 sg:person.01104460675.05 schema:affiliation grid-institutes:None
259 schema:familyName Barker
260 schema:givenName Roger A.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104460675.05
262 rdf:type schema:Person
263 sg:person.01143475656.63 schema:affiliation grid-institutes:grid.417815.e
264 schema:familyName Lazic
265 schema:givenName Stanley E.
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143475656.63
267 rdf:type schema:Person
268 sg:person.01244365253.48 schema:affiliation grid-institutes:grid.120073.7
269 schema:familyName Green-Thompson
270 schema:givenName Zeyn W.
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244365253.48
272 rdf:type schema:Person
273 sg:person.01256130314.05 schema:affiliation grid-institutes:grid.5335.0
274 schema:familyName Mason
275 schema:givenName Sarah L.
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256130314.05
277 rdf:type schema:Person
278 sg:person.013473241432.70 schema:affiliation grid-institutes:grid.415036.5
279 schema:familyName Rowe
280 schema:givenName James B.
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013473241432.70
282 rdf:type schema:Person
283 sg:person.01364457173.35 schema:affiliation grid-institutes:grid.5335.0
284 schema:familyName Rubinsztein
285 schema:givenName David C.
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364457173.35
287 rdf:type schema:Person
288 sg:person.0703455320.69 schema:affiliation grid-institutes:grid.120073.7
289 schema:familyName Pugh
290 schema:givenName Peter J.
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703455320.69
292 rdf:type schema:Person
293 sg:pub.10.1038/ng0893-398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001162353
294 https://doi.org/10.1038/ng0893-398
295 rdf:type schema:CreativeWork
296 grid-institutes:None schema:alternateName John Van Geest Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 0PY UK
297 schema:name Addenbrooke’s Hospital, Hills Road, Cambridge, CB21 2QQ UK
298 Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK
299 John Van Geest Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 0PY UK
300 rdf:type schema:Organization
301 grid-institutes:grid.120073.7 schema:alternateName Addenbrooke’s Hospital, Hills Road, Cambridge, CB21 2QQ UK
302 schema:name Addenbrooke’s Hospital, Hills Road, Cambridge, CB21 2QQ UK
303 rdf:type schema:Organization
304 grid-institutes:grid.415036.5 schema:alternateName Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK
305 schema:name Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ UK
306 rdf:type schema:Organization
307 grid-institutes:grid.415163.4 schema:alternateName Fulbourn Hospital, Fulbourn, Cambridge, CB21 5EF UK
308 schema:name Fulbourn Hospital, Fulbourn, Cambridge, CB21 5EF UK
309 rdf:type schema:Organization
310 grid-institutes:grid.417815.e schema:alternateName Quantitative Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG UK
311 schema:name Quantitative Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG UK
312 rdf:type schema:Organization
313 grid-institutes:grid.5335.0 schema:alternateName Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA UK
314 UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY UK
315 schema:name Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
316 Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA UK
317 UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY UK
318 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...